Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab Nov 02, 2020
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer Oct 26, 2020
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners Oct 19, 2020
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat Oct 08, 2020
Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020 Oct 01, 2020
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy) Oct 01, 2020
Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients Sep 22, 2020
